Category Reports Biotech

Release of new clinical data from two Phase 3 trials (COMP005 and COMP006) on COMP360 in TRD + management webcast
Tradable short-term event: additional clinical data (specific portions of studies) and official management narrative. This is the type of event that changes the perception of probability/quality of clinical evidence, and thus volatility too.

Next catalyst
H1 2026 – Updated ELIMINATE-B Phase 1/2 data in chronic hepatitis B (PBGENE-HBV), including higher-dose biopsy readouts.
Secondary 2026 catalyst: first sites activated and initial multi-patient data from the FUNCTION-DMD Phase 1/2 trial of PBGENE-DMD after FDA IND clearance (Study May Proceed) in February 2026.

Aldeyra Therapeutics (NASDAQ: ALDX) is a clinical-stage biotechnology company developing modulators of reactive aldehyde species (RASP) for immune-mediated and metabolic diseases. The key late-stage asset is reproxalap, an ophthalmic RASP modulator for dry eye disease (DED) and allergic conjunctiviti

A parallel “year of truth” roadmap for Iovance Biotherapeutics (IOVA), ImmunityBio (IBRX) and Altimmune (ALT), three names with huge retail followings, real science on the table and very little room for execution mistakes.

Denali Therapeutics is moving into the most delicate phase of its evolution: from a blood–brain-barrier platform story to a commercial-stage rare-disease company. The centre of gravity is tividenofusp alfa (DNL310), a TransportVehicle-enabled enzyme replacement therapy for Hunter syndrome (MPS II) designed to address both systemic and central nervous system manifestations, something that current standard ERTs cannot do.

TuHURA announces that Kintara’s REM-001 trial in metastatic cutaneous breast cancer has met its primary safety endpoint in ten patients with early signs of clinical efficacy. This triggers the contractual milestone under the Kintara CVR Agreement and unlocks the distribution of 1,539,958 HURA shares to legacy Kintara shareholders holding CVRs.

Maze trades as a high-expectations play on APOL1-mediated kidney disease: the stock has rerated into a roughly mid-cap valuation on the back of a very strong balance sheet and the upcoming proof-of-concept data from the HORIZON Phase 2 trial in a broad AMKD population. The key tension now is simple: can the first substantive MZE829 dataset justify how far the share price has already come.

The FDA has sent a Complete Response Letter (CRL) for RGX-121 (clemidsogene lanparvovec) in MPS II, rejecting the BLA under the accelerated approval pathway and questioning the external control, the neuronopathic eligibility criteria and the CSF HS D2S6 biomarker. Management plans a Type A meeting and aims to resubmit, but the ultra-rare MPS II path is now longer and more complex, against a backdrop of recent clinical holds on the company’s ultra-rare MPS programs.

Ensysce Biosciences has provided a new operational update on its pivotal Phase 3 trial PF614-301, which evaluates PF614, a next-generation oxycodone prodrug, in patients with moderate to severe acute pain following abdominoplasty surgery. The company reports that the study has now enrolled 50% of the subjects targeted for the planned interim review, a meaningful operational milestone for a small clinical-stage pain company trying to move an abuse- and overdose-resistant opioid toward the market.